August 31, 2023: PD Neurotechnology® was present as an exhibitor at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, on August 27-31, 2023. This was the 5th consecutive participation of PD Neurotechnology® at the global MDS congress, where they have been an active exhibitor since 2019.

During the MDS Congress, the PD Neurotechnology® team organized a presentation where Movement Disorder specialists from various countries had the opportunity to learn about the latest developments regarding PD Monitor® and the real-world evidence data from its usage, which bring us closer to a paradigm shift in Parkinson's Disease Management.

Real-world, device-reported outcomes from a 6-month, continuous telemonitoring paradigm for Parkinson's disease, collected by 267 patients and 77 physicians were presented, suggesting that patients can benefit from improved OFF-time when integrating this paradigm into medical practice. Furthermore, it was explained how Parkinson's disease gait impairment can be accurately detected both by pressure- sensing insoles and IMU-based wearables with extremely high agreement between the two measurements.

In another publication presented, comparing in-office clinical assessments using the MDS-UPDRS rating scale and sensor-based home monitoring, showed moderate to strong correlations were observed for most symptoms (bradykinesia, rest tremor, gait impairment, and freezing of gait), as well as for fluctuating conditions (dyskinesia and OFF). For the first time, an objective index capable of remotely measuring patients’ quality of life, based on motor status was identified. The high accuracy of the PDMonitor®  was once more explained, validated through clinical trial data, confirming its effectiveness as an easy-to-use continuous telemonitoring solution.

During a multimodal clinical trial, using various telemonitoring tools, PDMonitor®  assessments were found to report symptoms in more detail and potentially allow more efficacious treatment recommendations.

Finally, evaluating Parameters of the TUG Test based on Data from IMU and UWB Sensors was presented, where parameters of the Timed Up and Go test can be accurately estimated both by Ultra Wide Band radars and IMU-based wearables with high agreement between the two measurements.

Another important point presented was physician satisfaction from PDMonitor® use. PDMonitor®, reporting helped them evaluate patients' symptoms and make decisions about therapeutic interventions better, faster, without being a burden to their clinical work and without requiring the patients to limit their daily activities, while Real-world data of 12 months showed high adherence to using the PDMonitor® for PD telemonitoring.

Furthermore, PD Neurotechnology® presented one conference abstract about an analysis of real-world, device-reported outcomes from patients in Greece, following a 6-month, continuous telemonitoring paradigm for Parkinson’s disease:

G. Rigas, N. Kostikis, A. Ntanis, F. Kanellos, K. Tsamis, S. Konitsiotis, D. Fotiadis. Evaluating continuous monitoring in Parkinson’s disease through real-world, device-reported outcomes. [abstract]. Mov Disord. 2023; 38 (suppl 1).

Professor Konitsiotis, Founder and Medical Director of PD Neurotechnology®, commented: “It was a pleasure to showcase our work that provides evidence that introducing continuous telemonitoring in clinical practice can lead to alleviation of PD symptoms, with the patients’ monitoring duration and the physicians’ experience being important factors. The outcomes show great promise & we firmly believe that PDMonitor® is bringing us one step closer to a paradigm shift in Parkinson's Disease Management.”

Nikos Moschos, Founder and Business Director of PD Neurotechnology® also noted:

“PDMonitor®, our game- changing device that provides continuous monitoring for Patients with Parkinson’s Disease and its continuous use in telemedicine protocols has proven, through published & emerging evidence, that it can lead to alleviation of PD symptoms.

We remain more committed than ever in a better world for Parkinson’s patients all over the world”

From left to right at the booth:

Professor Spyridon Konitsiotis: Founder & Medical Director, PD Neurotechnology®

Becky Duong: Clinical Application Specialist – UK, PD Neurotechnology®

Dilek Caglar: Country Manager- Turkey, PD Neurotechnology®

Antonis Papadimitriou: Senior Sales and Marketing Executive PD Neurotechnology®

Florian Wagner: CEO – PARIMED GmbH

Nikos Moschos: Founder & Business Director PD Neurotechnology®